<DOC>
	<DOCNO>NCT01990807</DOCNO>
	<brief_summary>The cure rate childhood acute lymphoblastic leukemia ( ALL ) increase significantly recent decade expect cure rate exceed 85 % . In recent year , Tyrosine Kinase Inhibitor ( TKI ) improve outcome Philadelphia chromosome positive ( Ph+ ) ALL . But high risk group , The prognosis patient still bad relapse rate high . Clearly , new therapy urgently need prevent /or treat relapse ALL .</brief_summary>
	<brief_title>Treatment Protocol Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>1 . The prognosis childhood acute lymphoblastic leukemia ( ALL ) increase . 2 . Tyrosine Kinase Inhibitor ( TKI ) improve Philadelphia chromosome positive ( Ph+ ) ALL treatment outcome . 3 . The prognosis high-risk childhood ALL except Philadelphia chromosome positive ( Ph+ ) ALL bad .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Children highrisk ALL Children low 18years old Bcr/Abl ( + ) Children middlerisk standardrisk ALL</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>high risk</keyword>
	<keyword>Philadelphia Chromosome absent</keyword>
	<keyword>Childhood acute lymphoblastic leukemia</keyword>
</DOC>